Endothelial cell angiogenic machinery

The endothelial cell angiogenic machinery is a complex, multi-component system responsible for the formation of new blood vessels from existing vasculature, a process known as angiogenesis (Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 438(7070), 932-936). This machinery encompasses a variety of signaling ligands, such as Vascular Endothelial Growth Factor (VEGF), Angiopoietins, and Fibroblast Growth Factors (FGF), along with their corresponding transmembrane receptors like VEGFR2 and Tie2 (Senger, D. R., & Davis, G. E. (2011). Angiogenesis. Cold Spring Harbor Perspectives in Biology, 3(8), a005090). These components work in concert to regulate endothelial cell proliferation, migration, and tube formation, while also interacting with the extracellular matrix through integrins and matrix metalloproteinases (MMPs). In healthy tissues, this process is tightly regulated to support wound healing and reproductive cycles, but it is frequently dysregulated in diseases such as cancer, where it facilitates tumor growth and metastasis (Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674). Pharmacological targeting of this machinery, primarily through VEGF inhibitors like bevacizumab or multi-kinase inhibitors like sunitinib, aims to disrupt these pathways to inhibit pathological vessel growth (Ferrara, N., & Adamis, A. P. (2016). Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 15(6), 385-403). However, therapeutic challenges include the development of drug resistance and significant side effects such as hypertension and impaired wound healing due to the systemic role of these pathways in vascular homeostasis.

Other names

Angiogenesis signaling pathwayAngiogenic machineryVascular endothelial signaling networkAngiogenic signaling cascade

The primary mechanism involves the inhibition of pro-angiogenic signaling, most commonly by sequestering ligands like VEGF-A or blocking the ATP-binding site of receptor tyrosine kinases such as VEGFR-2, thereby preventing downstream signaling for endothelial cell survival and migration (Ferrara, N., & Adamis, A. P. (2016). Nature Reviews Drug Discovery, 15(6), 385-403).